Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series
Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)
Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod
Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center study
